The practical relevance of our results was corroborated by the findings that KDM6A together with TRKA were upregulated in patient-derived CML cells, and in particular, KDM6A was further increased in CML samples from imatinib-resistant individuals. The gene discussed is KDM6A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.